| FAQ/Help |
| Calendar |
| Search |
| Today's Posts |
 |
|
Site Navigation
| ALS News & Research For postings of news or research links and articles related to ALS |
advertisement
| Reply |
|
|
Thread Tools | Display Modes |
|
|
| ALS News & Research For postings of news or research links and articles related to ALS |
| Reply |
|
|
Thread Tools | Display Modes |
05-19-2017, 01:31 PM
|
#1 | |||
|
||||
|
Grand Magnate
|
MT Pharma America Presents 12-Month RADICAVA™ (Edaravone) and Amyotrophic Lateral Sclerosis Data at the European Network for the Cure of ALS (ENCALS) Annual Meeting
MT Pharma America Presents 12-Month RADICAVA™ (Edaravone) and Amyotrophic Lateral Sclerosis Data at the European Network for the Cure of ALS (ENCALS) Annual Meeting | MilTech |
|||
|
 Reply With Quote
|
| Reply |
| Thread Tools | |
| Display Modes | |
|
|
Similar Threads
|
||||
| Thread | Forum | |||
| AB Science presents phase 3 data for masitinib in amyotrophic lateral sclerosis (ALS) | ALS News & Research | |||
| Edaravone (Radicava) for Amyotrophic Lateral Sclerosis (ALS) | ALS News & Research | |||
| MT Pharma America Announces FDA Approval of RADICAVAtm (Edaravone), the First New Tre | ALS News & Research | |||
| MT Pharma Presents Data on Edaravone for ALS at 2017 AAN Meeting | ALS News & Research | |||
| 12-month Edaravone Clinical Study Data in ALS Presented at the 27th International Sym | ALS News & Research | |||
MT Pharma America Presents 12-Month RADICAVAtm(Edaravone) and Amyotrophic Lateral Scl
Linear Mode
